Glypican-3 expression in clear cell adenocarcinoma of the ovary. - Wikidata - wikimedia - TriplyDB

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

http://www.wikidata.org/entity/Q44268931

about

Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma Current concepts in the immunohistochemical evaluation of liver tumors SALL4 expression in germ cell and non-germ cell tumors: a systematic immunohistochemical study of 3215 cases Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.Glypican-3: a new target for cancer immunotherapy.Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.Expression of Glypican 3 in low and high grade urothelial carcinomas.Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review).Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.Expression of Markers of Hepatocellular Differentiation in Pancreatic Acinar Cell Neoplasms: A Potential Diagnostic Pitfall.Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.Elevated GPC3 level promotes cell proliferation in liver cancer.

P2860

Q26772321-DEDFF260-8B57-4331-AADB-DAFD57E0DB21 Q26864205-6456CEE1-7F49-4627-8732-480C4492825F Q28307647-1A40C174-E20D-4898-BA44-629F7C61C147 Q33914169-33F05BA2-51E1-4750-A508-CFA520B96541 Q34000565-0A8FBB45-F9F0-4D13-9B15-B6920DE8D7AA Q34290698-597888D0-94AE-4266-996D-519BF5D19314 Q34372167-29A510EE-5A92-4791-8AAC-7460259A72A2 Q34543102-882B5BB4-07D8-41BD-A85C-17BB8CA9F63D Q35545814-310E7755-DA85-4579-8687-0892F40FF4E7 Q35552355-6E17DC24-E1CE-46A1-974E-3177DCCDEC9B Q35768137-EE0A9C7F-5F32-460C-B180-5C51FBF6902F Q35871283-02B86265-BB5C-4AEE-AA57-A45D8E3C2281 Q36469640-33165F0C-3761-4B18-85BB-DFAA57307514 Q37031710-63603F1A-F297-4705-A501-C7C3F522D58F Q37269461-8CDCC78C-4F37-4672-9AEF-183EE9650756 Q37475741-EADE145A-27A9-4874-A2A4-CDFC49CF55B9 Q37477273-EAD0FACB-0C62-45E7-976A-CDE15C40438E Q37645001-8B183369-4CF7-4588-A165-BA2D763D4B3B Q47115713-EE3DC675-98DA-4A14-8DDC-F10F410D6985 Q47118215-6D2A2C27-BE80-4BD0-9DB6-E21CF245D20A Q47696309-818BA33E-FB32-4E5F-9016-A0AC30A43D69 Q55405975-FC7BDA22-638C-4926-A084-4D1980AA41EB

P2860

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

http://www.wikidata.org/entity/Q44268931

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

@en

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

@nl

type

label

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

@en

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

@nl

prefLabel

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

@en

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

@nl

P1433

Q44268931-8AC58FA2-5DED-4B64-85DB-7D4205F41E15

P1476

Q44268931-C244A14E-7E5D-4952-8054-B2CB9AF54F06

P2093

Q44268931-13DC3535-F9C1-4024-A8AB-F7CCCEF380A9

Q44268931-1D9DFA8A-9FD0-488C-9555-0F4A0659BB5B

Q44268931-324AAF68-325D-457C-85B8-AC5B6F5749D0

Q44268931-33AFA228-619B-4F05-99E6-8ABBFEFE16E9

Q44268931-5675F162-9956-4FA1-8060-CBE9963721D1

Q44268931-9B82DF5A-5545-489E-8883-4181C1B68A1B

Q44268931-D71412CC-9895-4E3C-A69F-82A7D67D99CB

Q44268931-DFFB81D7-396C-4F4C-BBF8-AB854950AE09

Q44268931-F7CD6256-E9E2-4448-A4AA-5B0545F97BC8

P2860

Q44268931-031A011A-0C20-4BEB-9FCE-3CFF21036BA1

Q44268931-092428B9-70BB-414E-8881-CCBBDF0A40EE

Q44268931-2184B175-1119-4773-8868-2FE96A4B2ED6

Q44268931-23082796-9DD0-4004-AA58-96AF33639A16

Q44268931-33189F63-C97D-405F-AC2A-2AD2067C363E

Q44268931-43E21238-125A-4D52-8703-41E7DDBF68D1

Q44268931-46BBA677-51B0-4FF6-8722-06A8769FFFCE

Q44268931-52D5CB4D-08F2-411B-992D-EA447FB9EE8E

Q44268931-67AD953B-AF5F-4128-BCD4-A14ABFD2372E

Q44268931-73691D44-B52E-4A6E-8B93-6130B70869C7

P2888

Q44268931-BC7741C9-4448-4AAA-8A15-6AD194AB217A

P304

Q44268931-0AE1F7C8-609B-4047-804D-2274A012A40A

P31

Q44268931-7210FD7A-8C84-47B5-BEB1-5104FC46E75C

P356

Q44268931-DD7281C6-4B8C-4382-91E3-A53F034E613F

P433

Q44268931-DDA67B35-DD5D-48C3-A1A0-F773F35ABA3E

P478

Q44268931-4A2A2FD2-619F-451A-9E9B-AF5A3C8335DB

P577

Q44268931-74AE63B2-87D1-4813-857F-296A7CCE7D07

P5875

Q44268931-E679BF91-C234-420F-95ED-E82F765098C5

P698

Q44268931-42DE96CC-3FB5-4151-B867-AB1380E556D2

P921

Q44268931-A6C12E7C-E62C-4639-AE2B-41FBBCF51532

P356

MODPATHOL.2009.40

P1433

Modern Pathology

P1476

Glypican-3 expression in clear cell adenocarcinoma of the ovary.

@en

P2093

Daichi Maeda

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Aburatani

http://www.w3.org/2001/XMLSchema#string

Masashi Fukayama

http://www.w3.org/2001/XMLSchema#string

Satoshi Ota

http://www.w3.org/2001/XMLSchema#string

Shunsuke Nakagawa

http://www.w3.org/2001/XMLSchema#string

Tatsuhiko Kodama

http://www.w3.org/2001/XMLSchema#string

Tetsu Yano

http://www.w3.org/2001/XMLSchema#string

Yuji Taketani

http://www.w3.org/2001/XMLSchema#string

Yutaka Takazawa

http://www.w3.org/2001/XMLSchema#string

P2860

Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome

Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.

Glypicans: proteoglycans with a surprise.

Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.

Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation.

P2888

modpathol.2009.40

P304

824-832

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2009.40

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24242425

http://www.w3.org/2001/XMLSchema#string

P698

19329941

http://www.w3.org/2001/XMLSchema#string

P921